Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2016/5695641 http://scihub22266oqcxt.onion/10.1155/2016/5695641 C4769737!4769737!26981294     free     free     free       Case+Rep+Endocrinol 2016 ; 2016 (ä): ä Nephropedia Template TP {{tp|p=26981294|t=2016. Acute Kidney Injury Associated with Linagliptin |pdf=|usr=}}{{26981294}} gab.com Text Acute Kidney Injury Associated with Linagliptin JO: Case Rep Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=26981294 #FOAvip Linagliptin is a dipeptidyl peptidase-IV (DPP-IV) inhibitor that is approved for the treatment of type 2 diabetes mellitus. About 5% of linagliptin is eliminated by the kidneys and no dose adjustment is recommended in kidney impairment. We report a first case of linagliptin-associated acute kidney injury (AKI) in a patient with preexisting chronic kidney disease (CKD). We hypothesize that AKI was due to renal hypoperfusion from linagliptin-induced natriuresis and intravascular volume contraction in the setting of concomitant lisinopril use, which is known to impair autoregulation and potentiate hypotension-induced AKI. It may be prudent to exert caution and closely monitor kidney function when initiating linagliptin in combination with ACE-inhibitors in CKD patients. Twit Text FOAVip Acute Kidney Injury Associated with Linagliptin ????Case Rep Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=26981294 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26981294 #FOAvip English Wikipedia <ref>{{Cite pmid|26981294}}</ref> Acute Kidney Injury Associated with Linagliptin #MMPMID26981294 Nandikanti DK; Gosmanova EO; Gosmanov AR Case Rep Endocrinol 2016[]; 2016 (ä): ä PMID26981294show ga Linagliptin is a dipeptidyl peptidase-IV (DPP-IV) inhibitor that is approved for the treatment of type 2 diabetes mellitus. About 5% of linagliptin is eliminated by the kidneys and no dose adjustment is recommended in kidney impairment. We report a first case of linagliptin-associated acute kidney injury (AKI) in a patient with preexisting chronic kidney disease (CKD). We hypothesize that AKI was due to renal hypoperfusion from linagliptin-induced natriuresis and intravascular volume contraction in the setting of concomitant lisinopril use, which is known to impair autoregulation and potentiate hypotension-induced AKI. It may be prudent to exert caution and closely monitor kidney function when initiating linagliptin in combination with ACE-inhibitors in CKD patients. äAcute Kidney Injury Associated with Linagliptin (epmc).pdf DeepDyve Pubget Overpricing